Sars-CoV2 Clinical Trial
— GERONIMO 19Official title:
"STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE" GERONIMO 19
According to recent data, death rate is more than 20% for 75 years old hospitalized patients
and older.
In case of aggravation, according to the latest observations, if they are refused for
mechanical ventilation in intensive care, their death rate could reach 60% even for patients
without comorbidity.
Apart from an increase in oxygen therapy, no specific treatment is currently proposed.
The control of the inflammatory component seems to be a key element to be able to influence
the patients' health evolution.
Polyvalent intravenous immunoglobilins have immunomodulatory and anti-inflammatory properties
with a favorable safety profile for these elderly patients and several clinical cases lead to
positive impact in the caring for Covid patients.
This study objective is evaluation of the efficacy of polyvalent IVIg in combination with the
standard management of patients aged 75 and over with SARSCov2 infection with acute
respiratory failure (saturation ≤ 95%) requiring oxygen therapy> 5 L / min (i.e. patients
considered as moderate to severe ARDS according to the Berlin definition, Pa02 / Fi02≤200)
and disqualified from a care in the ICU.
Status | Recruiting |
Enrollment | 35 |
Est. completion date | May 5, 2021 |
Est. primary completion date | May 5, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 75 Years and older |
Eligibility |
Inclusion Criteria: - Man or woman aged 75 and over - SARS-coV2 infection confirmed by RT-PCR or thoraco-pulmonary CT - Hospitalized in the acute general geriatrics unit of the Versailles Hospital Center - Patient rejected from resuscitation - Saturation = 95% under oxygen therapy> 5 L / min (i.e. PaO2 / FiO2=200mmHg according to the Berlin definition of ARDS) by means of a nasal cannula, a high concentration facial mask or another device similar oxygen distribution Exclusion Criteria: - Patient under palliative care - Patient with contraindication to IV polyvalent Ig 1. . Hypersensitivity to the active substance or to any of the excipients (L-proline) 2. . Hypersensitivity to human immunoglobulins, especially when the patient has anti-IgA antibodies, 3. . Patients with type I or II hyperprolinemia - Patient under guardianship or curatorship - Patient receiving another experimental treatment as part of an interventional study - Moderate to severe dementia known: it must have been diagnosed before hospitalization and is defined by an MMSE <20/30 or a neuropsychological assessment with a diagnosis made. - Patient not affiliated with a social security system in France - ADL patients <4/6 and / or IADL <6/8 |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier de Versailles | Le Chesnay |
Lead Sponsor | Collaborator |
---|---|
Versailles Hospital |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mortality | Day 14 | ||
Secondary | Total number of days of full hospitalization | 3 and 6 months | ||
Secondary | Duration of oxygen therapy | 3 and 6 months | ||
Secondary | Ferritin level in the blood | 3 and 6 months | ||
Secondary | CRP level in the blood | 3 and 6 months | ||
Secondary | LDH level in the blood | 3 and 6 months | ||
Secondary | Lymphocyte level in the blood | 3 and 6 months | ||
Secondary | PNN level in the blood | 3 and 6 months | ||
Secondary | platelet level in the blood | 3 and 6 months | ||
Secondary | WHO performance index | 3 and 6 months | ||
Secondary | WHOQOL-OLD questionnaire | 3 and 6 months | ||
Secondary | Lung function by pulmonary computed tomography | 3 and 6 months | ||
Secondary | Lung function by EFR | 3 and 6 months | ||
Secondary | Mortality | 3 and 6 months | ||
Secondary | Readmission Rates | 3 and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04446065 -
Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers
|
Phase 2/Phase 3 | |
Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
Not yet recruiting |
NCT04400019 -
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
|
Phase 2/Phase 3 | |
Completed |
NCT04463004 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
|
Phase 2 | |
Completed |
NCT04446429 -
Anti-Androgen Treatment for COVID-19
|
N/A | |
Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 | |
Recruiting |
NCT04441372 -
Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
|
||
Recruiting |
NCT04581148 -
SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
|
||
Completed |
NCT04530604 -
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
|
Phase 1 | |
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
Active, not recruiting |
NCT04635605 -
Methylene Blue Treatment of COVID-19
|
Phase 2 | |
Recruiting |
NCT04395599 -
Risk of Air Contamination During Visceral Surgery in COVID19 Patients
|
N/A | |
Recruiting |
NCT04472585 -
Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04411433 -
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19
|
Phase 3 | |
Completed |
NCT04359706 -
Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
|
||
Recruiting |
NCT04395794 -
SARS-CoV-2 Disguise Study
|
||
Completed |
NCT04386551 -
Detection of COVID-19 in Saliva Collection
|
||
Withdrawn |
NCT04379492 -
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19
|
Phase 2 | |
Completed |
NCT04379336 -
BCG Vaccination for Healthcare Workers in COVID-19 Pandemic
|
Phase 3 | |
Completed |
NCT04366934 -
Study of the Pathogenesis of Olfactory Disorders in COVID-19
|